24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of VX-509, an oral JAK3 inhibitor,
for treatment of subjects with active RA who have had an inadequate response to Methotrexate.